BioSpace News Archive

AACC has issued a new guidance document with expert recommendations for performing point-of-care tests for fertility and reproductive health.

Leading physicians and researchers will present results from 21 clinical trials from Monday, October 31, to Wednesday, November 2, at the annual VIVA and The VEINS conferences at Wynn Las Vegas.

Foghorn® Therapeutics Inc., a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, announced management’s participation in upcoming investor conferences in September.

Prothena Corporation plc, a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced the appointment of Helen S. Kim, MBA, to its Board of Directors.

Chinook Therapeutics, Inc. announced that Chinook management is scheduled to participate in fireside chats and one-on-one meetings at the following upcoming investor conferences.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the 17th Annual Wells Fargo Securities Healthcare Conference taking place in Everett, MA from September 7-9, 2022.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia’s in vivo CRISPR/Cas9 genome editing candidate, NTLA-2002, for the treatment of hereditary angioedema (HAE).

Catalyst Biosciences, Inc. announced that the ex-dividend date for the special, one-time cash dividend of $1.43 per share to holders of the Company’s Common Stock previously disclosed by the Company will be September 21, 2022.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), announced three new data sets will be presented during Late-Breaking Clinical Trial sessions at the 2022 TCT (Transcatheter Cardiovascular Therapeutics) and the 2022 VEINS (Venous Endovascular Interventional Strategies) conferences.

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in September.